NCT07480915 Risk Stratification of MACE in Heart Failure Patients Who Undergoing CABG
| NCT ID | NCT07480915 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tomsk National Research Medical Center of the Russian Academy of Sciences |
| Condition | Heart Failure |
| Study Type | OBSERVATIONAL |
| Enrollment | 160 participants |
| Start Date | 2026-03-04 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 160 participants in total. It began in 2026-03-04 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
PROFILE-HF is a multicenter, observational, prospective study of the clinical course and outcomes of chronic heart failure (HF) and coronary artery disease (CAD) in patients undergoing coronary artery bypass grafting (CABG). The objective of the study is to develop a method for assessing the risk of adverse cardiovascular events in patients with CAD and HF who have undergone CABG, based on preoperative GDF-15 concentrations. The study will have a 12-month follow-up period; one in-person visit is planned at the end of the follow-up period. If it is not possible to visit a doctor in person, information will be collected through telephone contact with the patient or his relative or person caring for the patient.
Eligibility Criteria
Inclusion Criteria: * Heart Failure * Planned coronary artery bypass grafting Exclusion Criteria: * Myocardial infarction * Stroke * Presence of implanted devices; * Need for additional cardiac surgery other than coronary artery bypass grafting (valve repair, aneurysm); * Severe renal dysfunction (GFR \<30 ml/min/1.73 m2); * Severe comorbidities: active cancer; infiltrative cardiac diseases (sarcoidosis, amyloidosis, storage diseases); autoimmune diseases; acute infectious diseases and exacerbations of chronic somatic diseases.
Contact & Investigator
Alla A. Garganeeva, MD, PhD
PRINCIPAL INVESTIGATOR
Tomsk NRMC
Frequently Asked Questions
Who can join the NCT07480915 clinical trial?
This trial is open to participants of all sexes, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07480915 currently recruiting?
Yes, NCT07480915 is actively recruiting participants. Contact the research team at aag@cardio-tomsk.ru for enrollment information.
Where is the NCT07480915 trial being conducted?
This trial is being conducted at Tomsk, Russia.
Who is sponsoring the NCT07480915 clinical trial?
NCT07480915 is sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences. The principal investigator is Alla A. Garganeeva, MD, PhD at Tomsk NRMC. The trial plans to enroll 160 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.